Nanotherapy with hybrid liposomes for colorectal cancer along with apoptosis in vitro and in vivo

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 4701-4708

  Ichihara, Hideaki ^a   Nakagawa, Shinichiro ^b   Matsuoka, Yusuke ^b   Yoshida, Kenshi ^b   Matsumoto, Yoko ^a   Ueoka, Ryuichi ^a,b  

^a SOJO UNIVERSITY   (Japan)

^b Immuno medical Lab Omote Sando Yoshida Hospital   (Japan)

Author keywords

Apoptosis; Colorectal cancer; Hybrid liposome; Liver metastasis; Nanotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HYBRID LIPOSOME 25; LIPOSOME; POLIDOCANOL; POLYOXYETHYLENE; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; POLYOXYETHYLENE(25)DODECYL ETHER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CHEMICAL COMPOSITION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; THERAPY EFFECT; TUMOR XENOGRAFT; ULTRASOUND; ANIMAL; CELL PROLIFERATION; CHEMISTRY; COLORECTAL TUMOR; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; HYBRID LIPOSOME; LIVER METASTASIS; LIVER TUMOR; METABOLISM; METASTASIS; NANOTHERAPY; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

APOPTOSIS; COLORECTAL CANCER; HYBRID LIPOSOME; LIVER METASTASIS; NANOTHERAPY;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MICE; NANOMEDICINE; POLYETHYLENE GLYCOLS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908681861     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan, http://ganjoho.jp/pro/statistics/ en/gdb-trend.html?1%9
2. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, Defusco PA and Jochimsen P: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 11: 1879-1887, 1993.
3. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ and Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: 246-50, 1997.
4. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER and Fishier B: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from national surgical adjvant breast and bowel project C-04. J Clin Oncol 17: 3553-3559, 1999.
5. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK and Miller LL: Irinotecan plus fluorouracil/Leucovorin for metastatic colorectal cancer: a new survival standaed. The Oncologist 6: 81-91, 2001.
6. Hurwiz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350: 2335-2342, 2004.
7. Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, Jain R and Tebbutt NC: A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 108: 503-511, 2013.
8. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P: Efficacy according to biomarker status of cetuximab plus FPLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
9. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A and Goldberg RM: Effect of Oxaliplatin, Fluorouracil, and Leucovorin with or without Cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307(13): 1383-1393, 2012.
10. Ueoka R, Moss RA, Swarup S, Matsumoto Y, Strauss G and Murakami Y: Extraordinary micellar enantioselectivity coupled to altered aggregate sturucture. J Am Chem Soc 107: 2185-2186, 1985.
11. Ueoka R, Matsumoto Y, Robert A. Moss, Shanti Swarup, Sugii A, Harada K, Kikuchi J and Nurakami Y: Membrane matrix for the hydrolysis of amino acid esters with marked enantioselectivity. J Am. Chem Soc 110: 1588-1595, 1988.
12. Goto K, Matsumoto Y and Ueoka R: Hybrid liposomes coupled to steric control with high enantioselectivity. J Org Chem 60: 3342-3346, 1995.
13. Kitamura I, Kochi M, Matsumoto Y, Ueoka R, Kuratsu J and Ushio Y: Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study. Cancer Res 56: 3986-3992, 1996.
14. Yukihara M, Ito K, Tanoue O, Goto K, Matsushita T, Matsumoto Y, Masuda M, Kimura S and Ueoka R: Effective drug delivery system for duchenne muscular dystrophy using hybrid liposomes including gentamicin along with reduced toxicity. Biol Pharm Bull 34: 712-716, 2011.
15. Matsumoto Y, Kato T, Kemura Y, Tsuchiya M, Yamamoto Y and Ueoka R: Intracellular resuponses of hybrid liposomes against leukemia cells related to apoptosis with antitumor activity. Chem Lett 28: 53-54, 1999.
16. Iwamoto Y, Matsumoto Y and Ueoka R: Induction of apoptosis of human lung carcinoma cells by hybrid liposomes containing polyoxyethylenedodecyl ether. Int J Pharm 292: 231-239, 2005.
17. Matsumoto Y, Iwamoto Y, Matsushita T and Ueoka R: Novel mechanism of hybrid liposomes-induced apoptosis in human tumor cells. Int J Cancer 115: 377-382, 2005.
18. Ichihara H, Nagami H, Kiyokawa T, Matsumoto Y and Ueoka R: Chemotherapy using hybrid liposomes along with induction of apoptosis. Anticancer Res 28: 1187-1195, 2008.
19. Shimoda S, Ichihara H, Matsumoto Y and Ueoka R: Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo. Int J Pharm 372: 162-168, 2009.
20. Ichihara H, Matsuoka Y, Matsumoto Y and Ueoka R: Therapeutic effects of hybrid liposomes on the growth of gastric carcinoma involve apoptosis. Anticancer Res 30: 2011-2016, 2010.
21. Kitajima H, Komizu Y, Ichihara H, Goto K and Ueoka R: Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells. Cancer Med 2: 267-276, 2013.
22. Komizu Y, Matsumoto Y and Ueoka R: Membrane targeted chemotherapy with hybrid liposomes for colon tumor cells leading to apoptosis. Bioorg Med Chem Lett 16: 6131-6134, 2006.
23. Ishiyama M, Miyazono Y, Sasamoto K and Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44: 1299-1305, 1997.
24. Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K and Watanabe M: A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 36: 47-50, 1999.
25. Jeong JS, Lee SW, Hong SH, Lee YJ, Jung HI, Cho KS, Seo HH, Lee SJ, Park S, Song MS, Kim CM and Kim IH: Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin Cancer Res 14: 281-290, 2008.
26. Marshall JL: Managing potentially resectable metastatic colon cancer. Gastrointest Cancer Res 2: S23-S26, 2008.
27. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P and Engerran L: Resection of nonresectable liver merastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-520, 1996.
28. Aloia TA, Vauthey JN, Lover EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D and Abdalla EK: Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141: 460-466, 2006.
29. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O and Punt CJ: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572, 2009.
30. Díaz A1, González ML, Pérez RJ, David A, Mukherjee A, Báez A, Clearfield A, Colón JL: Direct intercalation of cisplatin into zirconium phosphate nanoplatelets for potential cancer nanotherapy. Nanoscale 5: 11456-11463, 2013.
31. Delie F1, Petignat P, Cohen M: GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Target Oncol 8: 225-230, 2013.
32. Ng TS, Wert D, Sohi H, Procissi D, Colcher D, Raubitschek AA, Jacobs RE: Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res 19: 2518-2527, 2013.
33. Huang SK1, Lee KD, Hong K, Friend DS and Papahadjopoulos D: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52: 5135-5143, 1992.